Good day, ladies and gentlemen. And welcome to your ENDRA Life Sciences Third Quarter 2020 Earnings Conference Call. All lines have been placed on a listen-only mode and the floor will be opened for your questions and comments following the presentation. At this time, it is my pleasure to turn the floor over to your host for today, Ms. Kim Golodetz. Ma'am, the floor is yours.

Thank you, Jess. This is Kim Golodetz with LHA, ENDRA’s recently engaged investor relations firm. Good afternoon and welcome to ENDRA’s third quarter 2020 business update and financial results conference call. ENDRA issued a press release on this topic earlier this morning. For those of you who don’t have a copy of the release, you can access it in the Investors section of ENDRA’s website at www.endrainc.com.

Thank you, Kim. Good afternoon, everyone. Thank you for joining us today to review ENDRA’s third quarter 2020 performance and 2020 business update. Along with David and me on today’s call are Renaud Maloberti, ENDRA’s Chief Commercial Officer; Michael Thornton, Chief Technology Officer and as I mentioned, David Wells, our CFO. Let me go through today's agenda. First I'll highlight our recent achievements including major milestones achieved in the last week before handing it over to David to review the financials. Then Renaud will provide details on commercial activities with an initial focus on Europe where we have our first regulatory approval and finally, we'll open the call for Q&A. For those of you who may be new to the ENDRA story, we're the pioneer of thermo acoustic enhanced ultrasound also known as TAEUS. TAEUS is a disruptive technology platform that allows clinicians to quickly visualize tissue in ways similar to an MRI, but at 50 times lower cost. TAEUS is simple to use as it can complete scans within minutes at the point of patient care. It works with existing ultrasound systems, which are in widespread global use. We have a collaboration with GE healthcare, which supports our commercialization plans, but TAEUS is compatible with all major manufacturers of ultrasound. As we've shared before, there is an acute need for practical tool like TAEUS to assess and monitor liver fat to help more than one billion people globally affected by nonalcoholic liver disease or NAFLD and nonalcoholic steatohepatitis also called NASH. Accordingly the NAFLD, NASH diagnostic market is our primary initial focus and I continue to be very encouraged by our progress this year.

Thank you, François. Our third quarter 2020 financial results are as follows. Our operating expenses increased to $3.3 million for the quarter ended September 30, 2020 up from $2.6 billion for the same period in 2019. This includes a total of $600,000 for non-cash charges mainly equity compensation. Our research and development spending increased year-over-year by approximately $300,000 as we prepared our TAEUS system for commercial launch, including the necessary regulatory approvals and our sales and marketing costs increased by a nominal $40,000 for the quarter as COVID-19 restrictions limited travel and in-person attendance at industry conferences. Our general and administrative costs increased by approximately $275,000 due to employment-related expenses, which included non-cash charges for stock compensation. Additional spending on costs associated with being a publicly traded company including investor relations and increased costs for insurance. Our net operating loss for the quarter ended September 30, 2020 was $3.3 million as compared to a net loss of $2.6 million for the quarter ended September 30, 2019. The portion of our net loss attributable to common shareholders, which includes funding-related non-cash charges was $3.7 million and $3.4 million for the quarters ended September 30, 2020 and 2019 respectively. In Q3 2020, this amount is related to the exercise of certain outstanding warrants. Our operating net loss also includes non-cash charges, which totaled $1.9 million for Q3 2020 and are comprised primarily of charges for equity-based compensation and amortization of debt discount. Our net loss per share for the quarter ended September 30, 2020 was $0.15 per share. Our cash balance at September 30, 2020 was $3.8 million. This after raising approximately $5 million in the early exercise of warrants held by long-term shareholders during this quarter. We remain diligent and vigilant, balancing our available cash and needs for cash against our outstanding equity and capitalization structure. We have and will continue to approach this balancing in several ways. First, by managing our burn rate through reductions where possible as we did in April with wage and fee to stock conversions by our management and Board of Directors. We will spend only which we feel is prudent and focused on the market success for TAEUS. Second, by not allowing our balance sheet to consume cash unnecessarily for fixed assets or poorly timed increases in inventory. This is what we mean when we have said in the past of our asset-light operating and third, by maintaining active communication with our longtime shareholders, building relationships with potential new investors and continuing to refine and retool the message on ENDRA value to the market. This remains a critical path activity for ENDRA and will be for some time to come.

Thank you, David. From a commercial perspective, following the receipt of the CE mark throughout the third quarter we accelerated our efforts in CE the market and building our brand to start the commercialization of ENDRA's TAEUS in Europe. In the US, we continued building awareness in advance of FDA clearance. As Francois mentioned in his opening remarks, our commercial strategy centers on three key elements. The first commercial element is to establish evaluation sites in key markets. Despite the month-long COVID-19 impact on normal operation for healthcare facility, our team successfully secured our first European evaluation site at the Johannes Gutenberg University outside Frankfort German during the quarter. We are also in the final legal review evaluation sites in France and Switzerland and expect to finalize this agreement to restore yearend. We'll formally announce the site when they start scanning patients in the coming month and contingent on European business operations remaining open in light of COVID. One good example of our progress on this key commercial front is the news announced last week that our TAEUS system is now installed at Rocky Vista University. This is our first installation in the US and it will be followed in the coming weeks with installations at the other evaluation sites, namely the University of Pittsburgh Medical Center and the Medical College of Wisconsin. The data from these studies and evaluation sites will be used to bolster the clinical evidence and further establish the clinical utility of TAEUS. Of the TAEUS ultrasound device in patients with NAFLD to help accelerate commercialization in Europe and eventually the US once the FDA clearance is secured. The second commercial element centers on building a small European sales team to work alongside GE sales teams. On our last quarterly call, we announced that we hired…

Thanks very much Renaud and David. I'll wrap up the call before Q&A by emphasizing we're happy to deployed our first clinical system in the US and remain focused on ramping up commercialization activities in Europe, supporting the FDA review of our 510-K submission in the US and exploring partnerships in the pharmaceutical sector. Look forward to providing investors with updates in the coming weeks and months as we make specific progress on all these fronts. With that, I'd like to open up the call for questions, operator?

Thank you. We'll move first to Brooks O'Neil of Lake Street Capital Markets.

I have a couple questions, recognizing the obvious disruption of COVID both here in the US and internationally, first I guess do you see -- are you getting any indications from FDA that approval isn’t likely on the normal timeframe and if they did, roughly when might we see that approval? And then, just talk a little bit about Europe, Francois, I recognize that based on my conversations with other companies that the COVID spikes have resulted in more aggressive shutdowns in many country in Europe. How do you think that is going to affect your efforts to commercialize the system in say the first half of 2021?

Yeah so regarding FDA, as we pointed out on the call, we've not gotten any indication from the FDA that there are issues they have engaged with us quite proactively on various normal questions and beyond that, I couldn't say when approval might come. I don’t want to speak to the approval cycles. All I know is clearly approval cycles typically turn around the six month mark from filing. It's possible with the COVID-19 situation that the FDA is at times de-focused but we've not experienced that. So I remain very optimistic about receiving clearance and we'll certainly update investors on any material changes that occur going forward. Second, regarding EU and COVID, I don't want to make excuses. No one can control COVID and the reality for us is we need to do what we're able to do and so that's involved recruiting good people as we've done now in the UK and just recently in Germany and building that pipeline of people so that we can actually as seen on the ground. The legal discussions on the evaluation sites in Europe continue also when we don't need to be there in person and as Renaud mentioned, we've been continuing to build on the momentum to raise awareness and interest since really starting this process and going to at least 14 clinical conferences globally since 2018. So it's important to remember that clinicians as well as administrators, as well as companies like ENDRA and GE and others are hampered and the world has changed, but in a sense work where it's a great equalizer these virtual booths that we are using are we're finding very cost-effective to get the message out. We're getting a good deal of interaction. Clinicians are attending, participating and we've got a good exchange and a good amount of lead collection. I don't want to minimize the impact of COVID. Clearly there's concern, but I will say just from the one sample that we've had now for a couple of months with our UK sales rep, He's very active. He's engaging, clinicians are now fully engaged on Zoom and other virtual conferences. He's making development calls, commercial development calls and I think that that will bode well for commercial sales. We're not yet ready to signal when those sales will occur, but certainly we're in the process of making those sales calls and remain optimistic that 2021 will be a full commercial year for ENDRA. I don't know if that answers your question.

That's great. So let me just shift gears a little bit and ask you a little bit about the capital position. Number one, great job on the raising the $5 million through the warrants, I am curious if there are -- if you expect or think there is any more from that well if you will. Number two, I'm curious what your expectation is with regard to your renegotiations with GE. A, could they be a capital partner and B, are you pretty sure they'll sign up again in 2021 and then C, the comment you made about the drug partnerships and drug opportunity feel very encouraging and full of potential and I am curious if you just obviously on a preliminary basis, if you see the potential to have some kind of a financial partnership that would help on the capital side as well?

So Brooks, let me tackle the GE and the pharma question and then I'll ask David Wells to speak a little bit more in detail to the capitalization specific question, but what I can share with you about GE is as you know I and many people on the management team and the board are ex-employees of GE. We've strong relationships there and our contacts at GE both remain stable and remain committed to helping ENDRA, the liver space for all the reasons I've mentioned is equally clearly an opportunity for GE and other players. They see the opportunity to improve tools to screen and monitor patients with liver disease. So GE's focus in liver remains strong. I don't want to signal more than simply I believe the contract will be renewed, but certainly as we advance both through the commercialization ramp, building clinical evidence, that the relationship with GE certainly has potential to get deeper and I believe in time, it will and I publicly stated that our goal is not to be in the box and accessory business long-term. We have to prove our clinical and commercial uptake to start with the installed base of enhancing ultrasounds, but longer-term, our goal is to be in the licensing of TAEUS to o companies like GE and otherwise. So I believe that we remain on that track. Your second point about pharmaceutical companies, yeah I remain really bullish about that opportunity. It seems to have really reopened in terms of since the beginning of the year and pharmas and contract research organizations that run these clinical trials for NAFLD, NASH drugs are approaching us and saying as I think I said on the last call, we're not looking to replace MRI yet, but cheap, easy, safe tool could really be attractive for us. So I would say let's manage an initial collaboration with a goal of partnering, getting data, having the pharmaceutical companies prove that value in their clinical trials and I could see that growing in 2021 to a potentially strategic investment and commercial relationship, but let's go one step at a time and I'm excited about I think getting that first step started very soon. I hope that helps. David if you could speak a little bit to Brooks' initial question. That will be super.

Sure and actually I'll kind of pick up where you left off, which is the statement one step at a time and that's really what we're doing now and establish choices as I talked about earlier whether it be unregistered warrants, which indirect answer to your question are there additional warrants that are exercisable and the answer is yes. And then add to it various market-based funding opportunities, those are available to us from the strategic partnerships and non-dilutive academic research grants. I think the trick here is to keep taking one step at a time to see how the company is being perceived in terms of overall value. See how the market is responding to some of the unique things of 2020, COVID and others and continue to make our best decision. I'm very proud and I think it's borne out in our capitalization structure. So I am very proud of the decisions we as a company have made over the years. We've made good decisions about how we're going to capitalize ourselves and we're going to continue to make those good decisions.

That's great, David. Thanks for all that color.

Thanks again Brooks. Operator, do we have any more questions.

We'll move next to Ed Woo at Ascendiant Capital.

My question is on the reference sites, evaluation sites, do you have plans beyond the three initial in the US and three that you guys targeted for Europe?

Yeah thanks Ed. Great question. So I'm really -- our thinking in terms of how fast we've scaled that is how well can we support it and what are we learning. So it's more a question of I think staging multiple sites over time. The answer is yes. We want to have a reference site in each target market the UK, France, Germany, Italy, Switzerland and others, but we also want to support them well and we want to learn in the process and so staggering them gradually over time is beneficial that way. In the US, we have three sites the Mid-Atlantic University of Pittsburg Medical Center, the Midwest Medical College of Wisconsin and in the Southwest, the installation at Rocky Vista University; that gives us a good geographic distribution and if you remember our criteria for selecting these sites was one, geographic because clinicians in France or clinicians in the Northeast like to hear about data and potentially want to go and visit and kick the tires of the unit in clinical use at a site near them. So that's one reason. The other elements were we want these evaluators to clearly see the same potential for tool like ours and as I've mentioned, several of the evaluators including University of Pittsburgh, which is a liver center of excellence approached us at the American Association for study of Liver Disease Conference. So we view them as real partners. Objective, they must be objective. We don't run these studies. We don't control them, but they have the right interest and interest in making a successful case for their patients as well as for ENDRA and other clinicians. So yes, the answer is we'll continue to build out additional sites as we are able to support them with a focus initially on Europe and in the US. I hope that answers your question Ed.

Yes it does and then in terms of each evaluation sites, how much involvement of both resources and money is involved for you guys to participate?

Yeah great question. So I won't reveal how much we are paying per patient because that's obviously confidential, but I will say that GE has been very helpful in providing us as one example of how they're working with us with ultrasound systems that we don't have to buy and so we are deploying turnkey systems to these sites, our own system plus GE ultrasound system to enable a speedy and as I mentioned turnkey operation of these sites and these sites as I have also mentioned will scan a number of patients ranging from 75 scanned to up to 200 scanned on MRI PDFS which is the gold standard from a research perspective and then scanned on our system so that we can have a comparison to a very good measure and we expect these studies to take typically as I've said six to nine months. So we'll see the results of this study start to come out in the end of the first half next year, but in the meantime I also want to emphasize that commercially we're not waiting for that data to come out. Those are reference sites, evaluation sites and our salespeople in each country are actively soliciting customers in our contract customer relationship management database and being introduced to customers by GE. So it's something that's happening in parallel to our commercial sales. Once those evaluation sites complete their studies, we fully expect and will work very hard obviously to keep them happy and satisfied that they will become commercial sites for us and commercial customers and I want investors to think about revenue for us next year not in terms of 1Z, 2Z type of sales associated with our sales reps, but really site-wide healthcare system wide type of sales and without at all inferring that UPMC has made a commitment this way, it's public information that UPMC is a large healthcare system with at least 40 hospitals. So getting our foot in the door, generating goodwill, proving the case with our technology, I believe sets us up for a stronger, potentially commercial relationship. That's not the case today, but I want investors to start thinking ahead and good commercial relationship with a site like UPMC could turn into a very substantial bulk buy for ENDRA. Okay. Hope that's helpful Ed.

Yes that was very helpful and I wish you guys good luck. Thank you.

With no other question holding, Mr. Michelon, I'll turn the conference back to you for any additional or closing comments.

Yeah thanks very much Jess. thank you everyone for joining us this evening. We're very excited about ENDRA's future and we're pleased to have shared our plans with you this afternoon. I do want to mention that we do have an active Investor Relations program and are available for virtual meetings with the investment community. Please contact LHA, our IR partners if you'd like to schedule a meeting and also I want to mention that we're participating in two investment community conferences this week. Tomorrow November 17, we'll be presenting at the Virtual investor Summit at 130 Eastern Time and on Thursday, November 19, we'll be participating in AGP's Virtual Healthcare Conference, which is a one-on-one format. Thank you again everyone. I wish you well and good afternoon.

Ladies and gentlemen, that will conclude today's programming. We thank you for your participation. You may disconnect at this time and have a great day.